An observational study in Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD) and Necrotizing Enterocolitis (NEC), sponsored by Göteborg University. Enrolling by invitation at 1 site in Sweden. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Göteborg University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Retinopathy of Prematurity with a site in Sweden — 1 open to participants now, 2 under way, none of them phase 3. Retinopathy of Prematurity · Sweden.
Among the 10 studies in Retinopathy of Prematurity with a site in Sweden, this one is the only one that started in 2026, is one of 2 observational ones, and was the 10th registered.
170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.
Browse Retinopathy of Prematurity studies →1 of the 10 studies in Retinopathy of Prematurity with a site in Sweden is open now.
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: Up to 28 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,100 is above the median of 183 across 58 observational studies indexed under Retinopathy of Prematurity.
Median enrollment 107 across the 8 interventional studies, 2,059 across the 2 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Göteborg University is the lead sponsor of 272 studies on the registry; 47 are open to participants now.
Göteborg University has 2 studies filed under Retinopathy of Prematurity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Retinopathy of Prematurity with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Babies born extremely preterm (before 28 weeks of pregnancy) miss most of the transfer of two long-chain fatty acids, arachidonic acid (ARA) and docosahexaenoic acid (DHA), that normally passes from mother to baby in the last three months of pregnancy. Low levels of these fatty acids after birth have been linked to retinopathy of prematurity (ROP), an eye disease that can threaten vision, and to other complications of prematurity. In a Swedish randomized trial (Mega Donna Mega), an enteral supplement of ARA and DHA reduced severe ROP by about half. A similar supplement, NeoMega36, is now used in routine care in several European neonatal units and is being introduced in Sweden.
This observational study examines whether the introduction of NeoMega36 into routine care is followed by less ROP and fewer other complications of prematurity. It compares infants born at 22+0 to 27+6 weeks of gestation who were cared for before NeoMega36 was introduced at their unit (historical period) with infants cared for after it was introduced (NeoMega period).
The study has two parts:
The study does not give, assign or change any treatment. NeoMega36 is given as part of routine clinical care according to each unit's own practice. There are no extra examinations, visits or contacts with families.
The main hypothesis is that the proportion of infants with severe ROP is lower in the NeoMega period than in the historical period. Other outcomes are treated ROP, any ROP, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), death before discharge, and the combined outcomes BPD or death and NEC or death. Because this is a before-and-after comparison, differences between the periods may also reflect other changes in care over time, and the results will be interpreted with this in mind.
DESIGN NeoMega-REAL is a multicentre observational before-and-after (pre/post-implementation) study with two components that share objectives and outcome definitions but are analysed separately: a European component based on aggregated unit-level data and a Swedish component based on individual-level national register data.
EXPOSURE The exposure is implementation of NeoMega36 (an enteral supplement of arachidonic acid and docosahexaenoic acid in a 2:1 ratio) in routine care at the unit. Each unit defines a Historical period before local implementation (preferably 24 months, ideally about twice the length of the NeoMega period, and not overlapping it) and a NeoMega period starting after local implementation (at least 12 months). The main comparison is between periods, regardless of whether an individual infant received the supplement. Within the NeoMega period, units may report how many eligible infants did and did not receive NeoMega36; these counts describe implementation coverage only and are not used for comparative outcome analyses, because receipt can depend on the infant's clinical condition (for example feeding intolerance or nil per os). For each unit, the implementation date, local eligibility criteria, dose regimen, start and stop criteria, handling of interruptions and common reasons for non-use are recorded.
EUROPEAN COMPONENT (AGGREGATED DATA) Participating European neonatal units that have implemented NeoMega36 complete a standardized datasheet (NeoMega-REAL Datasheet Template v2.0). For each period and each gestational week at birth (22+0 to 22+6 up to 27+0 to 27+6, plus all infants), units report counts of eligible infants, infants screened for ROP, severe ROP, treated ROP, any ROP, BPD at 36 weeks postmenstrual age by Jensen grade, NEC (surgical NEC separately where available), death before discharge, BPD or death, and NEC or death. Units also describe, for each period, the use of human milk fortifiers and preterm formula and whether these contain DHA and/or ARA, other routine lipid or fatty-acid supplements, and major changes in feeding or other clinical protocols between periods. Only aggregated counts are submitted: no individual-level data, dates of birth, identifiers or code keys. Units apply the same local definitions in both periods and report any changes in definitions. Data collection from units runs from June to November 2026.
SWEDISH COMPONENT (REGISTER DATA) All infants born before 28 completed weeks of gestation and cared for at Swedish neonatal units during defined periods before and after national implementation of NeoMega36 (from the third quarter of 2026) are identified through the Swedish Neonatal Quality Register (SNQ), which records neonatal characteristics, NeoMega36 exposure and neonatal morbidity, linked with SWEDROP, the national register for retinopathy of prematurity, which records ROP screening, severity and treatment. Data are coded (pseudonymized) and the register holder keeps the code key. Register data are planned to be retrieved annually for about five years after implementation, with the first extraction planned for the third quarter of 2027. Neurodevelopmental data from routine follow-up programmes may later be analysed as an exploratory outcome. No extra examinations, sampling, visits or contacts with children or guardians take place.
DATA QUALITY The coordinating centre checks plausibility and internal consistency (for example, ROP counts not exceeding the number screened, composite outcomes not lower than their components, NeoMega36 given plus not given approximately equal to the total, and complete, non-overlapping period dates). Discrepancies are resolved through queries to the unit and documented in a query log. Files are version-controlled and stored with restricted access on University of Gothenburg secure storage.
STATISTICAL ANALYSIS European component: a two-stage approach. Within each unit, odds ratios for the NeoMega versus Historical period, adjusted for gestational week, are estimated from the aggregated counts; unit-level estimates are pooled by random-effects meta-analysis, and between-unit heterogeneity is assessed (including the I-squared statistic). As a sensitivity analysis, a binomial mixed-effects model with logit link is fitted to the aggregated data, with gestational week as fixed effect and neonatal unit as random effect. Analyses are performed for all infants and by gestational week where data allow. Further sensitivity analyses, where feasible: restriction to units with comparable period lengths and stable screening criteria; exclusion of gestational weeks or units with sparse counts; and alternative denominators for ROP outcomes (infants screened versus all eligible infants). Secondary outcomes are analysed in the same framework where data completeness and event numbers allow. Unit-level nutrition variables are summarized descriptively and may be used in sensitivity analyses.
Swedish component: outcome frequencies are compared between periods overall and by gestational age, using regression models adjusted for background characteristics and calendar period where data allow. Results may be reported separately from, and interpreted alongside, the European results.
SAMPLE SIZE All eligible infants in the defined periods are included. The European component is expected to include about 200 to 300 infants per period in its first phase. Based on Swedish data, 151 infants per period give 80% power (two-sided alpha 0.05, 1:1) to detect a 50% reduction in severe ROP from an incidence of 27.1% among infants born before 28 weeks of gestation.
TIME PERSPECTIVE (OTHER) The European component is retrospective: units report outcomes for infants already born and cared for during the defined periods. The Swedish component is prospectively defined: the post-implementation cohort accrues after national implementation in 2026, and its data are recorded in routine care and retrieved from national registers.
SAMPLING (NON-PROBABILITY) The participating European units are units that have implemented NeoMega36 and agreed to take part. Within each unit, and nationally in Sweden, all consecutive eligible infants born during the defined periods are included, without individual-level selection.
INTERPRETATION Differences between periods cannot be attributed solely to NeoMega36, since changes in case mix, survival, nutrition and other clinical practice over time may also contribute. The study evaluates outcomes after implementation in routine care; it does not estimate an individual-level causal treatment effect.
ETHICS The study has been approved by the Swedish Ethical Review Authority (Dnr 2026-02384-01). Each participating unit is responsible for any local approvals required to share aggregated routine data.
Infants born extremely preterm, at 22+0 to 27+6 weeks of gestation, cared for (1) at European neonatal units that have introduced NeoMega36 into routine care, during defined periods before and after local implementation, and (2) at Swedish neonatal units during defined periods before and after national implementation of NeoMega36, identified through the Swedish Neonatal Quality Register (SNQ) and SWEDROP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period before NeoMega36 was introduced into routine care at that unit (European units: preferably 24 months, not overlapping the NeoMega period; Sweden: a defined period before national implementation). Infants received standard nutrition according to local practice.
Infants born at 22+0 to 27+6 weeks of gestation and cared for at a participating neonatal unit during a defined period after NeoMega36 was introduced into routine care at that unit (European units: at least 12 months; Sweden: from national implementation in 2026). All eligible infants in this period are analysed in this group whether or not they individually received NeoMega36; the numbers given and not given the supplement are reported only to describe uptake.
Dietary Supplement: Enteral arachidonic acid and docosahexaenoic acid supplement
Enteral lipid supplement containing arachidonic acid (ARA) and docosahexaenoic acid (DHA) in a 2:1 ratio (NeoMega36, Neobiomics, Solna, Sweden), given in routine neonatal care according to each unit's local protocol for eligibility, dose, and start and stop criteria. The supplement is not assigned, provided or changed by the study. Exposure is defined at period level as implementation of NeoMega36 in routine care at the unit.
Also known as: NeoMega36
Severe retinopathy of prematurity (ROP)
Number and proportion of infants with ROP stage 3 or higher and/or treated for ROP (ICROP/ETROP-based routine practice), among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week (European component: pooled across units by random-effects meta-analysis; Swedish component: regression analysis of register data). The sample size calculation is based on this outcome.
Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age
Treated retinopathy of prematurity (ROP)
Number and proportion of infants who received ROP treatment (for example anti-VEGF injection and/or laser), regardless of stage or type, according to local practice, among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week.
Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age
Any retinopathy of prematurity (ROP)
Number and proportion of infants who developed ROP of any stage, among infants with a final ROP screening outcome. Compared between the NeoMega and Historical periods as an odds ratio adjusted for gestational week.
Time frame: From birth until completion of ROP screening (final screening outcome), usually by about 40 to 45 weeks postmenstrual age
Bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age, by Jensen grade
Number and proportion of infants with BPD graded by respiratory support at 36 weeks postmenstrual age (Jensen et al. 2019): no BPD, no support; grade 1, nasal cannula at 2 L/min or less; grade 2, nasal cannula above 2 L/min or non-invasive positive airway pressure; grade 3, invasive mechanical ventilation. Among infants alive at 36 weeks postmenstrual age; compared between the NeoMega and Historical periods.
Time frame: At 36 weeks postmenstrual age
BPD or death before 36 weeks postmenstrual age (composite)
Number and proportion of infants with BPD at 36 weeks postmenstrual age or death before BPD assessment, each infant counted once. Compared between the NeoMega and Historical periods.
Time frame: From birth to 36 weeks postmenstrual age
Necrotizing enterocolitis (NEC)
Number and proportion of infants with NEC as documented in routine care. Compared between the NeoMega and Historical periods.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
Surgical necrotizing enterocolitis (NEC)
Number and proportion of infants with NEC requiring surgery, where reported. Compared between the NeoMega and Historical periods.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
NEC or death before discharge (composite)
Number and proportion of infants with NEC or death before discharge, each infant counted once. Compared between the NeoMega and Historical periods.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
Death before discharge
Number and proportion of infants who died before discharge from neonatal care. Where available, death before the final ROP screening outcome and death before 36 weeks postmenstrual age are also reported. Compared between the NeoMega and Historical periods.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
Uptake of NeoMega36 during the NeoMega period
Number and proportion of eligible infants who received and did not receive NeoMega36 during the NeoMega period, with aggregated reasons for non-use where available. Descriptive only; not used for comparative outcome analyses.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
Other neonatal morbidities in the Swedish cohort
Occurrence of other prematurity-related complications recorded in the Swedish Neonatal Quality Register, such as sepsis and patent ductus arteriosus, compared between the NeoMega and Historical periods.
Time frame: From birth until discharge from neonatal care, assessed up to 12 months of age
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The European component collects only aggregated unit-level counts, so no individual participant data are held by the investigators. Swedish individual-level data are pseudonymized data released by the national quality registers (SNQ and SWEDROP) for this approved project only; other researchers can apply for these data directly from the register holders, subject to ethical approval. Aggregated results will be published.
Started Jun 2026 (actual). Primary completion is estimated for Aug 2031, 61 months after the start.
Of 26 observational studies under Retinopathy of Prematurity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 61 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.